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The dopamine agonists ropinirole and pramipexole exhibit highly speciﬁc aﬃnity for the cerebral dopamine D3 receptor. Use
of these medications in Parkinson’s disease has been complicated by the emergence of pathologic behavioral patterns such as
hypersexuality, pathologic gambling, excessive hobbying, and other circumscribed obsessive-compulsive disorders of impulse
control in people having no history of such disorders. These behavioral changes typically remit following discontinuation of the
medication,furtherdemonstratingacausalrelationship.ExpressionoftheD3receptorisparticularlyrichwithinthelimbicsystem,
where it plays an important role in modulating the physiologic and emotional experience of novelty, reward, and risk assessment.
Converging neuroanatomical, physiological, and behavioral science data suggest the high D3 aﬃnity of these medications as the
basis for these behavioral changes. These observations suggest the D3 receptor as a therapeutic target for obsessive-compulsive
disorder and substance abuse, and improved understanding of D3 receptor function may aid drug design of future atypical
antipsychotics.
1.Introduction
An association between neurodegeneration of the dopamin-
ergic nigrostriatal system and the major motor symptoms of
Parkinson’sdisease(PD)wasﬁrstrecognizedin1960[1]after
pioneering work by Arvid Carlsson showed that L-DOPA
reversed the parkinsonian syndrome in rabbits induced by
reserpine [2]. This observation led to the ﬁrst trials of
injected levodopa (L-dopa), a direct metabolic precursor
of dopamine, to address motor symptoms associated with
the disease. This treatment demonstrated transient success,
but was impractical due to severe toxicities associated with
the injections. Gradual titration of oral L-dopa was better
tolerated, but was still associated with severe nausea and the
requirement of higher doses of L-dopa due to peripheral
consumption of the substrate. In the 1970s, compounding
L-dopa with the peripheral dopa-decarboxylase inhibitor
carbidopa very successfully addressed these shortcomings.
Nausea and vomiting were reduced to such a degree that the
medication adopted the trade name Sinemet (sine=without;
emet = emesis). Compounded levodopa-carbidopa remains
the mainstay of treatment for PD.
Dopaminergic agonists are synthetic analogues of do-
pamine.ApomorphinewassuggestedforthetreatmentofPD
as early as 1884 [3], although the ﬁrst article describing its
eﬀectiveness was not published until 1951 [4]. Bromocript-
ine was found to be eﬀective in PD in 1974 [5]. Other ergo-
tamine dopamine agonists including lisuride, pergolide, and
cabergoline were subsequently found to be eﬀective. In the
1990s, two nonergot dopamine agonists (DA), pramipexole
and ropinirole, were granted approval for use in the United
States. These have been adopted by many clinicians for a
variety of reasons, including a more stable motor response,
improved side-eﬀect proﬁle, and more convenient dosing
schedule.
As DA medicines became widely used, unanticipated
reports of poorly modulated risk taking began to emerge,
and the link between these behaviors and the medications
was recognized by the year 2000 [6, 7]. These took the form
of compulsive gambling, hypersexuality, hyperphagia, and
even hobbying or shopping that took on an obsessive-
compulsive-type character. Examining the pharmacology of
these medications and their speciﬁcity to the D3 dopamine
receptors provides an opportunity to understand why these2 Parkinson’s Disease
pathological behaviors are not generally seen with levodopa,
why tardive movement disorders arise in many patients tak-
ing typical (dopamine-targeting) neuroleptics, and why the
recognition of DA-agonist-related pathological behaviors in
PD patients may suggest potential therapeutic targets for




Dopamine receptors have been divided into 5 diﬀerent sub-
types (D1–D5). Structurally, the D1 and D5 receptors are
very similar, while the D2, D3, and D4 receptors are
diﬀerentfromthem.Inparticular,theD3receptorhasstrong
representationinthelimbicsystemanditsconnectionsinthe
ventral striatum and is associated with cognitive, emotional,
and endocrine functions [8].
L-dopa increases the availability of dopamine in the
brain, without known speciﬁcity for a dopamine receptor
subtype. In contrast, the dopamine agonists ropinirole,
pramipexole, and pergolide exhibit high aﬃnity for the D3
receptors [9–11]. The older dopamine agonist, bromocrip-
tine, does not share this speciﬁcity and appears to have
greater aﬃnity for the D2 receptor [9].
This receptor speciﬁcity may have functional relevance
to the increased rates of pathological behaviors, as the D3
receptor expression is particularly rich in limbic areas and
often being coexpressed with D2 in regions serving sensory
(sensory thalamic nuclei), hormonal (mammilothalamic
tract), and association (amygdala) functions [12]. The D3
receptor appears to control the phasic, but not tonic, activity
of dopaminergic neurons which may be induced by novelty
or presentation of drug-conditioned cues in rodents [13–
15] .T h e s ed a t as e e mt oc o n v e r g eo na ni m p o r t a n tr o l e
for the D3 receptor in modulating the physiologic and
emotional experience of novelty, reward, and risk assessment
and likely explain the relatively higher rates of pathological
behaviorsamongpatientstakingDAs.Pathologicalbehaviors
associated with bromocriptine have not generally been
observed, with a single case report in 2003 being the ﬁrst
time this association was noted [16]. This likely reﬂects the
lower frequency of use and may also be understood in the
context of bromocriptine lacking the D3 speciﬁcity of the
more commonly utilized DAs. Animal models suggest that
D3 receptor stimulation is also involved in the emergence of
dopamine-induced dyskinesias [17, 18].
3.Pathological Behaviors
The most commonly reported pathological behaviors have
been pathological gambling, hypersexuality, compulsive or
binge eating, and compulsive shopping. Uncertainty remains
regarding the overall frequency of DA-associated behavioral
changes. Initial surveillance suggested very low rates—on the
order of 2%–8% [19]. Subsequent structured-questionnaire
ascertainments found higher rates, with a recent large ques-
tionnaire-based assessment reporting a rate of 13.6% [20].
This cross-sectional study assessed rates of pathologic gam-
bling(9.9%), compulsive sexual behavior(4.4%), compul-
sive buying(7.2%), and binge eating(5.6%) among current
DAusers,withatotalof17.1%ofcurrentDAusersexhibiting
anypathologicalbehavior.Thiscomparedtothesigniﬁcantly
lower rate of pathological behaviors(6.9%) among subjects
not using a DA for at least 6 months prior to enrollment.
Some authors argue that reliance on impersonal ques-
tionnaires or spontaneous patient reports likely results in
incomplete ascertainment due to the sensitive and/or poten-
tially embarrassing nature of these symptoms. Another
recentreportutilizedphysician-directedsymptomelicitation
and found pathological behaviors in 24% of patients using
DA at therapeutic doses and in 30% of patients using
“target” DA dosing [21]. Although involving a smaller
population than some other reports, this paper highlights
somediﬃcultiesincapturingbehavioralchangeswithseveral
patients exhibiting compulsive hobbying or computer use,
and others having poor insight into their behavioral changes
including a patient with compulsive gambling who perceived
his behavior as “beneﬁcial” due to net wins.
Emergence of pathological behaviors is very uncom-
monly seen among patients treated with L-dopa alone [22].
Alargestudyutilizingstructuredinterviewassessmentfound
pathological behaviors in 6.9% of subjects not currently
takingaDA,althoughpriorexposuretoDAwasnotreported
[20]. In previous reports, the DA with highest D3 aﬃnity
(pramipexole) appears to be more commonly implicated
in pathological behaviors both in PD and in restless legs
syndrome [23], but a large cross-sectional study found no
diﬀerence between current use and risk for pathological
b e h a v i o r sb e t w e e nD A s[ 20]. Again, prior DA exposures and
reasons for discontinuation were not reported.
The relationship between deep brain stimulation (DBS)
of the subthalamic nucleus (STN) and impulse control
disorders is complex, and it is the focus of several review
papers [24, 25]. In general, a reduction in dopaminergic
medication is seen after STN DBS, and with reduction
or elimination of dopamine agonist therapy ICDs such as
pathological gambling and others can improve [26–29].
However, several studies have noted de novo ICDs after DBS
[30–32]. Interestingly, models of STN function [33]s u g g e s t
that the STN modulates decision thresholds in proportion
to reinforcement and decision conﬂict. Patients with STN
DBS showed typical conﬂict-induced slowing in “win-win”
computerized decision-making tasks with their DBS oﬀ,
but 10 minutes after turning the DBS on, they exhibited
less slowing and increased impulsive decision making in
these same tasks [34]. Dopamine dysregulation syndrome
(DDS) is a compulsive overuse of dopaminergic therapy.
Preexisting DDS may or may not improve after STN DBS.
Lim et al. found DDS remained unimproved or worsened in
12/17 patients after DBS, although this was a mix of STN
and globus pallidus interna (GPi) DBS cases [32]. In the
remaining 5/17 patients, DDS improved or resolved.
Discontinuation of the DA or signiﬁcant adjustment
in dosage is the mainstay of treatment intervention and
appears to be required to achieve full remission or signiﬁcant
reduction in behaviors [35]. Even still, some patients exhibitParkinson’s Disease 3
persistent pathological behaviors. A study examining psy-
chosocial outcomes in patents having exhibited pathological
gambling found persistent ﬁnancial and marital stress as
a consequence of these behaviorsalthough full or partial
resolution of the behaviors in all subjects followed [36].
Some authors group DA-associated behavior changes
as disorders of impulse control, but careful examination
of the behavioral issues reported in the medical literature
and by our patients suggests a more complex behavioral
derangement than a general disorder of impulse control.
Patients appear to demonstrate a circumscribed obsessive-
compulsion for a particular behavior. Most commonly, pa-
tients exhibit one particular obsession, but even in cases
wheretwoormoreobsessionsmanifest,themorewidespread
injudicious decision making and excessive spontaneity that
characterize a general disorder of impulse control are absent
[20–23, 37, 38]. It may be that the neural systems mediating
these pathologic behaviors are more closely aligned with
punding (an intense fascination with meaningless move-
ments or activities such as collecting, arranging, or taking
apart objects), and one study suggested a strong relationship
between punding and the expression of dyskinesias. Some
studies suggest a D3 receptor-dependent response to L-dopa
and dyskinesia, at least in monkeys [13].
Several recent studies have documented the importance
of the brain circuits involved in reward and risky decision
making, including, thalamic, striatal, and ventromedial
frontalregions.UsingfMRI,Reuterandcolleaguescompared
pathological gamblers and control subjects and found that
activation in regions such as the ventral striatum is inversely
related to their pathological gambling severity, as if risks
and rewards were less salient to pathological gamblers except
at high enough magnitudes [39]. Another fMRI study
had subjects play a game in which they decided to keep
pumping up a virtual balloon or quit and collect reward
points, with larger rewards associated with larger balloons
[40]. Increased activation levels in insular, thalamic, striatal,
and dorsolateral prefrontal regions bilaterally and medial
prefrontal cortex/anterior cingulate regions correlated with
increases in active risk taking. Functional imaging studies in
PD patients have implicated similar brain regions [41, 42].
Voon et al. [38] studied PD patients with and without
impulse control disorders (ICD) in a risk task involving a
certain (e.g., +$100) or an uncertain outcome (e.g., 50/50
chance of winning either $200 or winning $0) for both gains
(+$) and loss (−$) domains. PD patients without impulse
control disorders behaved more similarly to healthy controls
while they were on DA medications, making substantially
more risky choices when they were confronted with losses
than with gains, thereby showing “loss aversion” [43]. These
same patients made highly similar choices in the gain versus
the loss domains without loss aversion when they were oﬀ
DA medications. PD patients with ICD showed more risk
taking in the gain domain whether on or oﬀ medication, a
pattern that was opposite to those of the healthy controls
and PD patients without ICD. Moreover, PD patients with
ICD also showed higher sensitivity to risk when they were
on DA medications, displaying a steeper drop in the number
of risky choices as the value at stake became higher and
higher. In another study [44], PD patients without ICD
were given the Iowa Gambling Task(IGT) while they were
on or oﬀ medications. In this task, subjects chose between
f o u rd e c k so fc a r d sw i t hv a r i o u sr i s kr e w a r dp a y o ﬀs(i.e.,
risk disadvantageous(RD) decks with larger and frequent
rewards but also infrequent large losses leading to long-term
net losses, versus risk advantageous(RA) decks with smaller
frequent rewards but also smaller infrequent losses leading
to long-term net gains). PD patients oﬀ DA medications
showed an appropriate decrease in choices for the risk-
disadvantageous(RD) decks over trials. In contrast, PD
patients on DA medications failed to show such outcome-
contingent learning; instead, they kept on choosing the RD
decks.
4. Implications for Other Disorders
Analogous behavioral changes arise spontaneously in the
general population, where they are often termed “obsessive-
compulsive disorder” or “addiction.” Obsessive-compulsive
behaviors emerge in 30–50% of patients with Tourette
syndrome [45], and recent PET imaging evidence suggests
widespread dysregulation of extrastriatal dopamine response
in subjects with Tourette syndrome relative to the response
in control subjects [46]. As discussed above, this suggests
a relationship between dysregulation of dopaminergic tone
and obsessive-compulsive behavioral manifestations.
The mainstays of pharmacologic treatment for obsessive-
compulsive disorder are antidepressant medications whose
primary pharmacologic target is thought to be serotonin
(5HT), a strategy that meets with varying success. Con-
sideration of the interaction between 5HT and dopamine
in the limbic system provides another perspective on how
these medications may be mediating that success. Rodent
studies implicate D2 and D3 receptor activity in models
of obsessive-compulsive behavior and found that D2/3
agonism ameliorated these behavioral models [47, 48]. The
emergence of similar behavioral drug-induced compulsive
b e h a v i o r si nP Dp a t i e n t sw i t hn oh i s t o r yo fs u c hb e h a v i o r s
and that the prevalence of these behaviors appears to
show a dose-dependent response adds further credence to
the relevance of dopaminergic stimulation in idiopathic
obsessive-compulsive behaviors. In addition to inhibiting
reuptake of 5HT and norepinephrine, clomipramine acts as
an antagonist at the D2 and D3 receptors, which may explain
in part the eﬃcacy of clomipramine in treating obsessive-
compulsive disorder. Taken together, these observations
suggest that modulation of speciﬁc dopaminergic receptors
may hold promise for new medications directed against
obsessive-compulsive behaviors.
Substance abuse literature suggests that liability to this
disorder exists in 9–12% of humans. The D3 receptor does
not appear to have a direct role in reinforcing the eﬀects of
drugs of abuse, but the role of the D3 receptor may be in
processing novelty and in the environmental conditioning
and associations that reinforce drugs of abuse, particularly
those with psychostimulant eﬀects. Initial studies in squirrel
monkeys [49] and in rats [50] suggest an important role
of the D3 and the closely related D2 receptor in mediating4 Parkinson’s Disease
drug-related discriminatory behaviors, but they provide no
evidence of a role of these receptors in direct reinforcement.
The studies also suggest a role for these receptors in
reinstatement of drug-use behaviors in abstinent animals.
Taken together, these data suggest a potential role for D2/D3
speciﬁc ligands in decreasing relapse rates in abstinent drug
abusers.
5. Conclusion
In the brief time since DAs have been widely used for
treatment of PD, an important association between higher
doses of these medications and the emergence of pathologic
behaviors has been recognized. As outlined above, the D3
speciﬁcity of these medications and over-representation of
the D3 receptor [51, 52] likely account for both the lower
incidence of dyskinesias and also for the emergence of
thesepathologicalbehaviors.Thisobservationhasimportant
consequences for the safe use and monitoring of PD patients
taking DA-agonists. Although the anatomical underpinning
of this neural connectivity is incompletely understood, this
observation also suggests potential therapeutic targets for
obsessive-compulsive disorder and possibly for substance-
based addictions. Advances in understanding the roles of
speciﬁc dopamine receptors may also help to guide drug
designforfutureatypicalneurolepticsthataimtoreduceside
eﬀects while improving eﬃcacy.
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